Trial · NCT05978544
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment Emergent Adverse Events | Study Day 58 | Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
| Secondary | Maximum serum concentration of Itolizumab, Cmax | Study Day 30 | Maximum serum concentration of Itolizumab |
| Secondary | Minimum serum concentration of Itolizumab, Cmin | Study Day 30 | Minimum serum concentration of Itolizumab |
| Secondary | Time to maximum serum concentration of Itolizumab, Tmax | Study Day 30 | Time to maximum serum concentration of Itolizumab |
| Secondary | Total Itolizumab exposure across time, AUC0-t | Study Day 30 | Total Itolizumab exposure across time |
| Secondary | Half life of Itolizumab, t1/2 | Study Day 30 | Half life of Itolizumab |
| Secondary | Inflammatory Markers,IL-6 | Study Day 30 | IL-6 |
| Secondary | Inflammatory Markers,TNF-α | Study Day 30 | TNF-α |
| Secondary | Inflammatory Markers, hs-CRP | Study Day 30 | hs-CRP |
| Secondary | Inflammatory Markers,Serum ferritin | Study Day 30 | Serum ferritin |
| Secondary | Inflammatory Markers,D-dimer | Study Day 30 | D-dimer |
| Secondary | CD6 receptor expression levels | Study Day 30 | Mean change of CD6 receptor expression levels in relative to baseline |
| Secondary | T cell subsets | Study Day 30 | Mean change of different T cell subsets in relative to baseline |
| Secondary | The proportion of patients with stable or improved Lung Function | Study Day 30 | Defined as patients with stable or improved PaO2 without increasing FiO2 in relative to baseline |
| Secondary | Mean change from baseline in Murray Score | Study Day 30 | Mean change of Murray Score in relative to baseline，The higher score means the worse outcome |
| Secondary | Mean change from baseline in SOFA score | Study Day 30 | Mean change of SOFA（Sequential Organ Failure Assessment） score in relative to baseline，The higher score means the worse outcome |
| Secondary | Mechanical ventilation-free days | Study Day 30 | Duration of non-Mechanical ventilation |
| Secondary | Oxygen therapy-free days | Study Day 30 | Duration of non-Oxygen therapy |
| Secondary | Duration of ICU stay | Study Day 30 | ICU stay days |
| Secondary | Mortality rate | Study Day 15, 30 | Defined as the proportion of patients who met fatal outcome event by Day 15 and 30 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05978544/registered